Pharmaceuticals, Biotechnology and Life Sciences
Transdermal technology specialist Futura Medicalis has made an – at least to say – interesting step in Saudi Arabia, country…
OptiBiotix Health is rearranging its directorial staff as it has changed its Commercial Director. Namely, Jim Laird will be substituted by Per Rehné to that directorial position.
Sanofi’s Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies.
J&J’s DePuy Synthes Products, Inc. has bought asset and signed development agreement with Interventional Spine, Inc., a privately held manufacturer…
Eli Lilly’s subsidiary Elanco US has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc’s (BIVI) U.S. feline, canine and rabies vaccines…
Sanofi has starts new year with big changes. In two separate statements the company announced closing a deal and ending a joint venture.
Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
Shire has entered a new year with a new non-executive director, as it has appointed Ian Clark to the board. His new duties started immediately.
In 2016, mega deals became ever more transformative.
German drug and crop chemical maker Bayer AG announced its $66 billion takeover of U.S. agrochemicals company Monsanto Co, while ChemChina signed a $43 billion acquisition of Swiss seeds group Syngenta AG, as consolidation in the sector intensified.
Analytical company Eurofins Scientific has broadened its testing facilities in Spain, as it is about to buy a Spanish pharmaceutical company Villapharma Research SL.